Bioasis Announces Non-Brokered Private Placement
The original release is unavailable here.
Bioasis Technologies Inc. on 6ix
Story so far
Earlier from Bioasis Technologies
- Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic
- Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor
- Bioasis Announces Publication of Independent Validation of the Company’s xB3 ™ Platform Technology
- Uptick Newswire’s “Stock Day” Podcast Welcomes Dr. Mark Day of Bioasis Technologies Inc.
- Bioasis Announces Closing of Second Tranche of Previously Disclosed Private Placement
Later from Bioasis Technologies
- Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 ™-001 Increased Brain Activity
- Bioasis Welcomes John E. Curran & David M. Wurzer to the Company’s Board of Directors
- Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018
- Bioasis Announces Closing of Previously Disclosed Private Placement
- Aeromics, Inc. Appoints Pharmaceutical and Biotech Veterans Mark Day, Ph.D. and Thomas Zindrick, J.D. to Its Board of Directors
Follow Bioasis Technologies into a list and get an email when it puts out news.
Follow Bioasis Technologies